Analgesics

Despite a decline in the number of COVID-19 cases, demand for analgesics continued to grow in 2023. This was partly due to the revival of pre-pandemic behavioural patterns, including the cessation of mask wearing and social distancing, which meant…

Analgesics remains the largest category in consumer health in Nigeria. Sales continued to rise in 2023, supported by strong brand positioning and consumer awareness. Other factors driving growth included affordability, widespread availability and a…

Analgesics experienced a rise in unit prices due to inflationary pressure, which pushed up the price of imported medications and locally-produced options. Current value growth accelerated in 2023 as a result of this trend. Brand loyalty remains…

Consumers are increasingly embracing self-medication, especially for minor illnesses, and this contributed to modest growth in 2023, as well as continuing population growth. Analgesics have achieved a substantial penetration rate in Cameroon,…

Analgesics is set to maintain steady current value growth in Brazil in 2023, and will remain the largest category within OTC, with a 40% share of value sales. The consumption of analgesics is mainly related to general pain, fever, and the relief of…

The reopened border between mainland China and Hong Kong in early 2023 had significant implications for the demand of analgesic remedies within the city, which rose considerably. This growth can be attributed to a shortage of analgesic remedies…

Towards the end of the review period, demand for analgesics was supported by the widening of the consumer base for these products as the advantages of using analgesics to manage headaches and other moderate types of pain became better known among the…

Analgesics is failing to record a strong performance in Lithuania in 2023; following the pandemic years, sales are stagnating, reflecting the saturated market and consumer base. In addition, a growing scepticism and concern about the overreliance on…

Analgesics has witnessed a return to positive volume growth in 2023, driven by the recovery of adult acetaminophen as a stronger flu season took hold in Switzerland. As the incidence of cold and flu increases, so does the use of analgesics in…

The topical analgesics/anaesthetic category is poised to record the fastest growth in volume and current value terms within analgesics in 2023, and looks set to show improved results in both respects as compared to 2022. These types of products…

The pandemic boosted demand for analgesics in Vietnam, as consumers believed that it was necessary to store analgesics at home as a precautionary measure. Adult and paediatric acetaminophen performed particularly well in 2020 and 2021, as…

Per capita consumption of analgesics continued to increase in Norway during 2023 after 2022 saw significant increases in consumption of these products. While there was some stockpiling of analgesics seen in Norway during the early stages of the…

Analgesics is expected to see a single-digit growth in current value terms in 2023. Sales are benefiting from the stable demand for analgesics and unit price increases linked to rising price lists as a result of the higher cost of production faced by…

Analgesics sales are returning to more normal patterns in 2023, following the fluctuations caused by the COVID-19 pandemic and the sharp price rises seen in 2022. On balance, current value growth rates are still elevated compared to pre-pandemic…

Following strong growth between 2020 and 2022, analgesics saw much more moderate current value growth in 2023 as the COVID-19 pandemic began to wane. Rising inflation as a result of the energy crisis stemming in part from the war in Ukraine is…

While analgesics are expected to register double-digit current value growth, constant value and volume growth is expected to be much more moderate, as inflation continues to be high. Any growth there is Chufa supported by population growth, as well…

The analgesics market in Bulgaria has reached a mature stage, characterised by steady growth and well-established product offerings. This maturity is evident in the consistent demand for pain relief solutions driven by factors such as an ageing…

In 2023, Australians suffered from an extended influenza season, with months where people were prone to sickness. Analgesics had already seen strong growth in the last few years due to widespread illness as a result of COVID-19.However, strong growth…

Analgesics has experienced a fluctuating performance in the last few years, as demand has been significantly impacted by the dramatic changes to consumer lifestyles resulting from the COVID-19 crisis. With the outbreak of COVID-19 in 2020, many…

Sales of analgesics return to their pre-pandemic performance in 2023. After the pandemic, seasonal colds and flus circulated more in the country as consumers socialised more without wearing masks, and sales of analgesics have returned to their usual…